Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2019

View Archived Issues

Viral-MS link comes via bad memories

Gut microbiome affects food allergies

Glucagon alpha-cell proliferation declines with age

Dengue virus protein mutation increases disease severity in mice

Patient enrollment ongoing in phase I study of MBS-301

New phase IIa ELEVATE 1 study investigates RVT-1201 for pulmonary arterial hypertension

Janssen Pharmaceutica presents PRMT5 inhibitors

First patient enrolled in IBT's pivotal phase III study of IBP-9414

NeuroVive announces the initiation of the second part of its ongoing phase Ia/b study of KL-1333

Nosopharm and Evotec partner to advance development of novel antibiotics

Vaccex to initiate clinical development of VX-001

Novel ERB antibiotics show promising activity in MRSA thigh infection models

LSS biallelic pathogenic variants are associated with APMR syndrome

Novel genetic variant in CARD11 as a biomarker of profound combined immunodeficiency

SP-8356, a CD147 inhibitor, is a potential compound for treating atherosclerosis

Aquaporin-1 is a potential therapeutic target in TBI, researchers find

Bristol-Myers Squibb patents TLR7, TLR8 and/or TLR9 antagonists

Janssen Biotech patent describes hSTING agonists

REVOLUTION Medicines identifies PTPN11 inhibitors

Pyramid Biosciences synthesizes NTRK1 inhibitors

Innovate UK grant supports ROP cancer vaccine development

FDA approves Xembify for primary immunodeficiencies

WDFY3 gene variants linked to mild to moderate neurodevelopmental delay and intellectual disability

Lasmiditan for acute treatment of migraine: results from phase III trial

EMA validates clinical development program for AB-8939

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...